These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36206989)

  • 1. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
    Samidurai A; Xi L; Das A; Kukreja RC
    Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.
    Das A; Durrant D; Salloum FN; Xi L; Kukreja RC
    Pharmacol Ther; 2015 Mar; 147():12-21. PubMed ID: 25444755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Multifaceted Potential of Sildenafil in Medicine.
    Pușcașu C; Zanfirescu A; Negreș S; Șeremet OC
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.
    Degjoni A; Campolo F; Stefanini L; Venneri MA
    J Thromb Haemost; 2022 Nov; 20(11):2465-2474. PubMed ID: 35950928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates.
    Poitras EL; Gust SL; Kerr PM; Plane F
    Curr Med Chem; 2021; 28(12):2418-2437. PubMed ID: 32964819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
    Ahmed WS; Geethakumari AM; Biswas KH
    Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
    Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
    Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets.
    Bajraktari G; Burhenne J; Bugert P; Haefeli WE; Weiss J
    Biochem Pharmacol; 2017 Dec; 145():54-63. PubMed ID: 28964803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients.
    Kniotek M; Boguska A
    J Immunol Res; 2017; 2017():4541958. PubMed ID: 28316997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
    Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
    World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
    Zhang WH; Zhang XH
    Asian J Androl; 2016; 18(5):723-31. PubMed ID: 26620458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
    Houslay MD
    Trends Cancer; 2016 Apr; 2(4):163-165. PubMed ID: 28741569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
    Mostafa T
    Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Cyclic GMP Export by Multidrug Resistance Protein 4: A New Strategy to Treat Erectile Dysfunction?
    Boydens C; Pauwels B; Vanden Daele L; Van de Voorde J
    J Sex Med; 2017 Apr; 14(4):502-509. PubMed ID: 28258955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.
    Biswas KH; Visweswariah SS
    J Biol Chem; 2011 Mar; 286(10):8545-8554. PubMed ID: 21193396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery.
    Andersson KE
    Br J Pharmacol; 2018 Jul; 175(13):2554-2565. PubMed ID: 29667180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
    Scaglione F; Donde S; Hassan TA; Jannini EA
    Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.